Consuelo Amantini
Overview
Explore the profile of Consuelo Amantini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
105
Citations
5855
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Luongo M, Marinelli O, Zeppa L, Aguzzi C, Morelli M, Amantini C, et al.
Cancers (Basel)
. 2025 Feb;
17(3).
PMID: 39898506
There was an error in the original publication [...].
2.
Maggi F, Giuliodori A, Brandi A, Cimarelli L, Alcantara R, Pallotti S, et al.
Appl Environ Microbiol
. 2024 Oct;
90(11):e0174024.
PMID: 39475287
Importance: The development of sequencing technologies has led to an exponential increase in microbial sequencing data. Accurately identifying bacterial species remains a challenge because of extensive intra-species variability, the need...
3.
Zeppa L, Aguzzi C, Morelli M, Marinelli O, Amantini C, Giangrossi M, et al.
J Pineal Res
. 2024 Jul;
76(5):e12997.
PMID: 39076059
Pancreatic ductal adenocarcinoma (PDAC) has poor prognosis and high mortality rates. Therefore, it is necessary to identify new targets and therapeutic strategies to improve the prognosis of patients with PDAC....
4.
Aguzzi C, Zeppa L, Morelli M, Marinelli O, Giangrossi M, Amantini C, et al.
Biofactors
. 2024 May;
50(6):1208-1219.
PMID: 38760945
Multiple myeloma (MM) is a blood cancer caused by uncontrolled growth of clonal plasmacells. Bone disease is responsible for the severe complications of MM and is caused by myeloma cells...
5.
Zeppa L, Aguzzi C, Morelli M, Marinelli O, Giangrossi M, Luongo M, et al.
Int J Mol Sci
. 2024 Feb;
25(4).
PMID: 38396679
Pancreatic ductal adenocarcinoma (PDAC) is the most frequent infiltrating type of pancreatic cancer. The poor prognosis associated with this cancer is due to the absence of specific biomarkers, aggressiveness, and...
6.
7.
Maggi F, Morelli M, Aguzzi C, Zeppa L, Nabissi M, Polidori C, et al.
Front Mol Biosci
. 2023 Mar;
10:1129202.
PMID: 36876044
Calcium flux is the master second messenger that influences the proliferation-apoptosis balance. The ability of calcium flux alterations to reduce cell growth makes ion channels interesting targets for therapy. Among...
8.
Morelli M, Nabissi M, Amantini C, Maggi F, Ricci-Vitiani L, Pallini R, et al.
Int J Mol Sci
. 2022 Dec;
23(23).
PMID: 36499683
The survival of patients with glioblastoma (GBM) is poor. The main cause is the presence of glioma stem cells (GSCs), exceptionally resistant to temozolomide (TMZ) treatment. This last may be...
9.
Wang J, Lamolinara A, Conti L, Giangrossi M, Cui L, Morelli M, et al.
Cancers (Basel)
. 2022 Aug;
14(16).
PMID: 36011047
The advent of trastuzumab has significantly improved the prognosis of HER2-positive (HER2+) breast cancer patients; nevertheless, drug resistance limits its clinical benefit. Anti-HER2 active immunotherapy represents an attractive alternative strategy,...
10.
Santoni G, Maggi F, Amantini C, Arcella A, Marinelli O, Nabissi M, et al.
Int J Mol Sci
. 2022 Jul;
23(14).
PMID: 35887088
Among brain cancers, glioblastoma (GBM) is the most malignant glioma with an extremely poor prognosis. It is characterized by high cell heterogeneity, which can be linked to its high malignancy....